Susan G. Komen® Applauds Bill Introduction; Urges Quick Passage
ANNAPOLIS – Susan G. Komen®, the world’s leading breast cancer organization, commends Senator Pamela Beidle (D-Anne Arundel)and Delegate Dana Jones (D-Anne Arundel) introducing legislation that would eliminate financial barriers to clinically appropriate genetic testing, as well as the recommended screenings based on the results of that testing.
Germline testing is a type of test that looks for inherited mutations that have been present in every cell of the body since birth. In the U.S., 5-10% of breast cancers are related to a known inherited gene mutation. The lifetime risk of breast cancer increases 20-49% for women with moderate risk inherited gene mutations and 50% or more for women with high-risk inherited gene mutations.
SB476/HB 830 introduced by Senator Beidle and Delegate Jones, eliminates the patient out-of-pocket costs for multi-gene panel testing for inherited gene mutations and evidence-based screenings, ensuring individuals have access to critical information regarding their lifetime cancer risk and recommended early detection and cancer surveillance.
“This legislation ensures patients have a better understanding their lifetime cancer risk and access to needed risk reduction and treatment strategies,” said Molly Guthrie, Vice President of Policy and Advocacy at Susan G. Komen. “Understanding cancer risk shouldn’t depend on financial means. This legislation helps eliminates barriers, empowering individuals with essential knowledge to make informed decisions about their health.”
“By eliminating the cost barrier to genetic testing, individuals can understand their health risks and make informed decisions about their own care while helping them stay vigilant to catch potential cancers down the road,” said Senator Beidle. “I am proud to sponsor this bill that will help individuals know their own cancer risk and ensure they have access to medically recommended early detection and cancer surveillance so that any treatment necessary can begin as soon as possible if needed”
“Every at-risk Marylander should have equitable access to evidenced based genetic testing. We know that early detection is key, and these medically recommended tests help save lives. I am proud to sponsor this legislation alongside Susan G. Komen and Chair Beidle,” said Delegate Jones.
Identification of inherited cancer risk can help guide decisions regarding recommended screenings for the early detection of cancer, personalized cancer treatments and risk-reducing medical treatments. Studies have shown an estimated 83% of eligible patients that underwent multigene panel testing had changes to their medical management, including modifications in follow-up and chemotherapy strategy.
